Sarepta公司CEO道格·英格拉姆即将卸任
Sarepta CEO Doug Ingram to step down
生物技术与制药领域的最新动态
Sarepta CEO Doug Ingram to step down
Gilead, Merck plan to debut new daily HIV pills
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug
Charles River sells its CDMO and European discovery businesses
Accent axes a cancer study; Werewolf considers its options
Alkermes CEO Richard Pops to retire after 35-year tenure
States sue Kennedy over US childhood vaccine overhaul
Novo Nordisk teams with Langer-founded biotech for oral obesity drugs
Polymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapy
GSK to buy pulmonary hypertension biotech 35Pharma for $950M
HHS commits up to $144M to study anti-aging approaches via ARPA-H
Novo Nordisk to slash Wegovy list price in half in 2027
Industry groups lay legal groundwork against pricing demos
UCLA spinout raises $11M to test microbiome-based weight loss therapy
Can the ACCESS pilot crack a longstanding barrier for startups?
BioMarin fails to find buyer, pulls Roctavian gene therapy off market
Patient dies in MacroGenics' cancer study, FDA puts trial on hold
Beam Therapeutics' new PKU program; Protara's bladder cancer data
Abcuro drug fails muscle weakness trial, development to continue
Immedica wins accelerated approval for once-rejected rare disease drug